PITTSBURGH, Sept. 23 - Resveratrol, the natural antioxidant commonly found in red wine and many plants, may offer protection against radiation exposure, according to a study by the University of Pittsburgh School of Medicine. When altered with acetyl, resveratrol administered before radiation exposure proved to protect cells from radiation in mouse models. The results of the research will be presented during the American Society for Therapeutic Radiology and Oncology's (ASTRO) 50th Annual Meeting in Boston.
The study, led by Joel Greenberger, M.D., professor and chairman of the Department of Radiation Oncology at the University of Pittsburgh School of Medicine, is overseen by Pitt's Center for Medical Countermeasures Against Radiation. The center is dedicated to identifying and developing small molecule radiation protectors and mitigators that easily can be accessed and administered in the event of a large-scale radiological or nuclear emergency.
"New, small molecules with radioprotective capacity will be required for treatment in case of radiation spills or even as countermeasures against radiological terrorism," said Dr. Greenberger. "Small molecules which can be easily stored, transported and administered are optimal for this, and so far acetylated resveratrol fits these requirements well."
"Currently there are no drugs on the market that protect against or counteract radiation exposure," he added. "Our goal is to develop treatments for the general population that are effective and non-toxic."
Dr. Greenberger and his team are conducting further studies to determine whether acetylated resveratrol eventually can be translated into clinical use as a radioprotective agent. In 2004, this same team of researchers identified the drug JP4-039, which can be delivered directly to the mitochondria, the energy producing areas of cells. When this occurs, the drug assists the mitochondria in combating radiation-induced cell death.
The abstract, "Acetylated resveratrol: A new small molecule radioprotector," will be presented at a poster discussion session at 5 p.m., Tuesday, Sept. 23.
The study was funded by a $10 million grant from the National Institute of Allergy and Infectious Diseases to establish the Center for Medical Countermeasures Against Radiation at the University of Pittsburgh.
The University of Pittsburgh School of Medicine is one of the nation's leading medical schools, renowned for its curriculum that emphasizes both the science and humanity of medicine and its remarkable growth in National Institutes of Health (NIH) grant support, which has more than doubled since 1998. For fiscal year 2006, the University ranked sixth out of more than 3,000 entities receiving NIH support with respect to the research grants awarded to its faculty. As one of the university's six Schools of the Health Sciences, the School of Medicine is the academic partner to the University of Pittsburgh Medical Center. Their combined mission is to train tomorrow's health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease and participate in the delivery of outstanding patient care.